IHC was employed to allocate 123 patients with DLBCL to two groups: mutant–type p53 (MUT-p53) and wild–type p53 (WT-p53) groups, of which MUT–p53 accounted for 26.0% (32/123) and WT–p53 accounted for 74.0% (91/123). This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.